Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102


CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses.

Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y.

Cancer Res. 2010 Feb 15;70(4):1459-68. doi: 10.1158/0008-5472.CAN-09-3798. Epub 2010 Feb 2.


The role of polymorphisms in circadian pathway genes in breast tumorigenesis.

Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, Zhang W, Chen K.

Breast Cancer Res Treat. 2011 Jun;127(2):531-40. doi: 10.1007/s10549-010-1231-2. Epub 2010 Oct 27.


The core circadian gene Cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling.

Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, Leaderer D, Holford T, Hansen J, Zhu Y.

Cancer Prev Res (Phila). 2010 Apr;3(4):539-48. doi: 10.1158/1940-6207.CAPR-09-0127. Epub 2010 Mar 16.


Polymorphisms in circadian genes, night work and breast cancer: results from the GENICA study.

Rabstein S, Harth V, Justenhoven C, Pesch B, Plöttner S, Heinze E, Lotz A, Baisch C, Schiffermann M, Brauch H, Hamann U, Ko Y, Brüning T; GENICA Consortium.

Chronobiol Int. 2014 Dec;31(10):1115-22. doi: 10.3109/07420528.2014.957301. Epub 2014 Sep 17.


Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk.

Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y.

Mol Carcinog. 2012 Dec;51(12):923-9. doi: 10.1002/mc.20862. Epub 2011 Oct 17.


Breast cancer risk, nightwork, and circadian clock gene polymorphisms.

Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, Cordina-Duverger E, Sanchez M, Arveux P, Kerbrat P, Richardson S, Guénel P.

Endocr Relat Cancer. 2014 Aug;21(4):629-38. doi: 10.1530/ERC-14-0121. Epub 2014 Jun 11.


Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2.

Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, Yi C, Holford TR, Zhu Y.

Cancer Res. 2009 Apr 15;69(8):3605-13. doi: 10.1158/0008-5472.CAN-08-4572. Epub 2009 Mar 24.


microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis.

Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y.

Cancer Res. 2009 Jul 15;69(14):5970-7. doi: 10.1158/0008-5472.CAN-09-0236. Epub 2009 Jun 30. Erratum in: Cancer Res. 2009 Aug 15;69(16):6758.


[Association of genetic variantions of circadian clock genes and risk of breast cancer].

Wang WM, Yuan P, Wang JY, Ma F, Fan Y, Li Q, Zhang P, Xu BH.

Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):236-9. doi: 10.3760/cma.j.issn.0253-3766.2013.03.017. Chinese.


The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications.

Mao Y, Fu A, Hoffman AE, Jacobs DI, Jin M, Chen K, Zhu Y.

Tumour Biol. 2015 May;36(5):3533-9. doi: 10.1007/s13277-014-2989-3. Epub 2015 Mar 5.


Loss of circadian clock gene expression is associated with tumor progression in breast cancer.

Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, Marchan R, Schmidt M, Rahnenführer J, Oster H, Hengstler JG.

Cell Cycle. 2014;13(20):3282-91. doi: 10.4161/15384101.2014.954454.


Entrainment of breast (cancer) epithelial cells detects distinct circadian oscillation patterns for clock and hormone receptor genes.

Rossetti S, Esposito J, Corlazzoli F, Gregorski A, Sacchi N.

Cell Cycle. 2012 Jan 15;11(2):350-60. doi: 10.4161/cc.11.2.18792. Epub 2012 Jan 15.


Cancer-related transcriptional targets of the circadian gene NPAS2 identified by genome-wide ChIP-on-chip analysis.

Yi CH, Zheng T, Leaderer D, Hoffman A, Zhu Y.

Cancer Lett. 2009 Nov 1;284(2):149-56. doi: 10.1016/j.canlet.2009.04.017. Epub 2009 May 19.


Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.

Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Ouellette G, Pichette R, Plante M, Tavtigian SV, Simard J.

BMC Cancer. 2006 Sep 29;6:230.


Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ERalpha) in response to therapeutic radiation.

Westbury CB, Reis-Filho JS, Dexter T, Mahler-Araujo B, Fenwick K, Iravani M, Grigoriadis A, Parry S, Robertson D, Mackay A, Ashworth A, Yarnold JR, Isacke CM.

J Pathol. 2009 Sep;219(1):131-40. doi: 10.1002/path.2581.


Potential cancer-related role of circadian gene TIMELESS suggested by expression profiling and in vitro analyses.

Mao Y, Fu A, Leaderer D, Zheng T, Chen K, Zhu Y.

BMC Cancer. 2013 Oct 25;13:498. doi: 10.1186/1471-2407-13-498.


CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines.

Zabouo G, Imbert AM, Jacquemier J, Finetti P, Moreau T, Esterni B, Birnbaum D, Bertucci F, Chabannon C.

Breast Cancer Res. 2009;11(1):R1. doi: 10.1186/bcr2215. Epub 2009 Jan 5.


Investigation of CD28 gene polymorphisms in patients with sporadic breast cancer in a Chinese Han population in Northeast China.

Chen S, Zhang Q, Shen L, Liu Y, Xu F, Li D, Fu Z, Yuan W, Pang D, Li D.

PLoS One. 2012;7(10):e48031. doi: 10.1371/journal.pone.0048031. Epub 2012 Oct 25.


Common genetic variants associated with breast cancer in Korean women and differential susceptibility according to intrinsic subtype.

Han W, Woo JH, Yu JH, Lee MJ, Moon HG, Kang D, Noh DY.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):793-8. doi: 10.1158/1055-9965.EPI-10-1282. Epub 2011 Mar 17.


Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.

Zeng H, Irwin ML, Lu L, Risch H, Mayne S, Mu L, Deng Q, Scarampi L, Mitidieri M, Katsaros D, Yu H.

Breast Cancer Res Treat. 2012 May;133(1):127-35. doi: 10.1007/s10549-011-1716-7. Epub 2011 Aug 12.


Supplemental Content

Support Center